Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The benefit-risk assessment of anticoagulation is individual and depends on many factors. A Dutch observational pilot study examined residual concentrations of dabigatran in seniors of different ages with atrial fibrillation to clarify the relationship between study results and clinical practice.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
